Syndax Pharmaceuticals
SNDX
242 hedge funds and large institutions have $2.36B invested in Syndax Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 95 increasing their positions, 77 reducing their positions, and 39 closing their positions.
839% more call options, than puts
Call options by funds: $26.1M | Put options by funds: $2.78M
23% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 77
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
9.27% more ownership
Funds ownership: 112.73% → 121.99% (+9.3%)
2% more capital invested
Capital invested by funds: $2.32B → $2.36B (+$41.4M)
5% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 39
2% less funds holding
Funds holding: 247 → 242 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$38.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$25.5M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$19.2M |
| 4 |
Goldman Sachs
New York
|
+$18M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$46.4M |
| 2 |
SC
Stempoint Capital
New York
|
-$28.4M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
-$8.18M |
| 4 |
Walleye Capital
New York
|
-$7.89M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.75M |
SNDX Hedge Fund Activity: Q2 2026 in Review
242 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2026, worth a combined $2.36B — up 1.8% from $2.32B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of SNDX and 37 opened new positions — a net loss of 2 holders — while 77 trimmed existing stakes and 95 added.
The largest buyer was Millennium Management, adding an estimated $38.6M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $46.4M sold.
- 242 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2026, down from 247 in Q1 2026.
- Funds reported $2.36B of Syndax Pharmaceuticals stock for Q2 2026, up 1.8% quarter-over-quarter.
- 37 funds opened new Syndax Pharmaceuticals positions in Q2 2026 and 39 closed out, a net change of -2 holders.
- The largest Syndax Pharmaceuticals buyer in Q2 2026 was Millennium Management, an estimated $38.6M added.
- The largest Syndax Pharmaceuticals seller in Q2 2026 was Point72 Asset Management, an estimated $46.4M sold.
Based on aggregated 13F filings for Q2 2026.